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Abstract 
Background and objective 
Cyclosporine has been observed to precipitate Cushingoid features in kidney transplant recipients already on 
prednisolone. Some pharmacokinetic studies have demonstrated increased prednisolone exposure in patients on 
cyclosporine therapy compared to azathioprine, whereas other studies have found no difference. The objective of this 
study was to determine whether cyclosporine impacts on prednisolone exposure as compared to tacrolimus. 
Methods 
Adult male kidney transplant recipients treated with prednisolone and either cyclosporine or tacrolimus were recruited 
for pharmacokinetic blood sampling at the out-patient clinic at the Princess Alexandra Hospital, Brisbane, Australia. 
Prednisolone plasma concentrations were determined using ultra high performance liquid chromatography. Dose 
adjusted area under the plasma concentration-time curve (AUC) of free and total prednisolone was estimated using a 
previously developed limited sampling strategy and non-compartmental analysis. 
Results 
A total of 55 patients were eligible for analysis; 38% received cyclosporine and 62% received tacrolimus co-therapy. 
No significant difference in mean dose adjusted total prednisolone AUC from 0 to 6 hours post-dose or mean dose 
adjusted free prednisolone AUC from 0 to 12 hours was observed between the cyclosporine and tacrolimus groups (449 
versus 428 nmol·h/L/mg, p=0.43 and 32 versus 30 nmol·h/L/mg, p= 0.51, respectively). 
Conclusion 
Cyclosporine does not change the dose adjusted exposure of prednisolone compared to tacrolimus. Adult kidney 
transplant recipients can therefore continue on their usual prednisolone dose when changing therapy between 
cyclosporine and tacrolimus.  
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1 Introduction 
  Cyclosporine is known to interact with a range of different drugs, with notable examples including 
statins [1, 2], digoxin [3, 4], ezetimibe [5], caspofungin [6] and aliskiren [7]. The unifying suspected mechanism for 
these interactions is cyclosporine inhibition of the efflux transporter P-glycoprotein (p-gp) and/or other efflux or influx 
transporters such as Organic anion transporter peptide 1B1 (OATP1B1) [1, 2]. Inhibition of prednisolone apparent 
clearance (CL/F) by cyclosporine, in the broad sense, was first hypothesised in 1984. This was based on the observation 
that kidney transplant patients on cyclosporine were more likely to display cushingoid appearance than patients on 
azathioprine. The authors tested this hypothesis and indeed found that the CL/F of total prednisolone was significantly 
higher in 27 kidney transplant recipients on azathioprine compared with 10 recipients on cyclosporine [8]. However, six 
subsequent studies, also using azathioprine as comparator, arrived at conflicting conclusions [9-14]. It therefore remains 
an open question whether or not cyclosporine inhibits the CL/F of prednisolone in solid organ transplant recipients. 
Given that prednisolone remains a cornerstone in immunosuppression therapy in solid organ transplantation, it is 
important to determine whether switching patients from or to cyclosporine affects prednisolone treatment. 
  We present a prospective pharmacokinetic study specifically designed to compare differences in dose 
adjusted exposure to free and total prednisolone in adult male kidney transplant recipients treated with either 
cyclosporine or tacrolimus. 
2 Methods 
2.1 Participants 
A prospective, observational cohort study was conducted between August 2011 and May 2012. Adult (≥18 
years) male kidney transplant recipients on a daily oral maintenance dose of prednisolone between 5 and 12.5 mg were 
recruited into the study. To be eligible, subjects were required to have had undergone living or deceased donor kidney 
transplantation at least 12 months prior to enrolment and be receiving ongoing outpatient follow-up at the Princess 
Alexandra Hospital, Brisbane, Australia. In addition, subjects had to be clinically stable and receiving concurrent 
immunosuppressant therapy with either cyclosporine or tacrolimus. Exclusion criteria included 1) a history of alcohol 
abuse or significant liver disease, 2) glucocorticoid therapy for any other reason apart from the prevention of rejection 
and 3) treatment with pulse steroids in the previous 2 months. On the day of blood sampling the patients’ medical 
history was recorded. Prednisolone and calcineurin inhibitor dose changes within the previous 7 days were not allowed. 
Medications were screened for p-gp and cytochrome P450 3A4 (CYP3A4) inhibitors/inducers. The study protocol 
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adhered to the declaration of Helsinki and was approved by the Princess Alexandra Hospital and University of 
Queensland Ethics Committees. All participants provided written informed consent. 
 
2.2 Drug analysis  
Each subject’s prednisolone exposure was measured on a single occasion in the outpatient setting. Prior to 
arrival at the hospital, subjects were instructed to consume a light, non-fatty breakfast. All blood samples were taken via 
a peripherally inserted intravenous cannula. Blood samples were collected in EDTA tubes immediately prior to, and 1, 
2, 4, and 6 hours after morning medications were taken. Plasma was prepared within 30 minutes by 10 minutes 
centrifugation at approximately 1750g. Plasma was stored at -20 °C. until analysis. Total and free prednisolone 
concentrations were determined in plasma using ultra high performance liquid chromatography (UHPLC) with tandem 
mass spectrometric detection [15]. For free prednisolone measurement, plasma ultrafiltrate was prepared by 
temperature-controlled ultrafiltration. Limit of quantitation for prednisolone was 5 nmol/L and linearity extended to 
2000 nmol/L. The intra-assay CV was <5% (4.9%, 3.9% and 2.3% for 23 nmol/L, 125 nmol/L and 533 nmol/L 
respectively) and the inter-assay CV <10% for all analytes.  
 
2.3 Estimation of exposure 
 It was decided a priori to estimate prednisolone exposure employing limited sampling strategies (LSS) 
previously developed in a cohort of kidney transplant recipients at the Princess Alexandra Hospital [16]. Total 
prednisolone AUC (area under the concentration-time curve) from 0 to 6 hours was estimated using equation 1:  
𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫 𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑫𝑫𝑨𝑨𝑫𝑫𝑨𝑨 𝑨𝑨𝑨𝑨𝑨𝑨𝟎𝟎−𝟔𝟔 𝒉𝒉𝑫𝑫𝑨𝑨𝒉𝒉𝑫𝑫𝑻𝑻𝑫𝑫𝑨𝑨𝑻𝑻𝑻𝑻 𝒑𝒑𝒉𝒉𝑫𝑫𝑨𝑨𝒑𝒑𝒑𝒑𝑫𝑫𝑫𝑫𝑻𝑻𝑫𝑫𝒑𝒑𝑫𝑫 = (𝟏𝟏𝟏𝟏.𝟏𝟏𝟏𝟏𝟏𝟏+𝟐𝟐.𝟗𝟗𝟎𝟎𝟔𝟔×𝑨𝑨𝟐𝟐+𝟐𝟐.𝟏𝟏𝟎𝟎𝟏𝟏×𝑨𝑨𝟒𝟒)𝑷𝑷𝒉𝒉𝑫𝑫𝑨𝑨𝒑𝒑𝒑𝒑𝑫𝑫𝑫𝑫𝑻𝑻𝑫𝑫𝒑𝒑𝑫𝑫 𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫   
,where C is the total prednisolone concentration sampled after 2 and 4 hours. Free prednisolone AUC from 0 to 12 
hours was estimated using equation 2: 
𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫 𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑫𝑫𝑨𝑨𝑫𝑫𝑨𝑨 𝑨𝑨𝑨𝑨𝑨𝑨𝟎𝟎−𝟏𝟏𝟐𝟐 𝒉𝒉𝑫𝑫𝑨𝑨𝒉𝒉𝑫𝑫𝑭𝑭𝒉𝒉𝑫𝑫𝑫𝑫 𝒑𝒑𝒉𝒉𝑫𝑫𝑨𝑨𝒑𝒑𝒑𝒑𝑫𝑫𝑫𝑫𝑻𝑻𝑫𝑫𝒑𝒑𝑫𝑫 = (𝟏𝟏.𝟎𝟎𝟗𝟗+𝟎𝟎.𝟕𝟕𝟗𝟗×𝑨𝑨𝟏𝟏+𝟏𝟏.𝟗𝟗𝟏𝟏×𝑨𝑨𝟐𝟐+𝟒𝟒.𝟒𝟒𝟗𝟗×𝑨𝑨𝟒𝟒)𝑷𝑷𝒉𝒉𝑫𝑫𝑨𝑨𝒑𝒑𝒑𝒑𝑫𝑫𝑫𝑫𝑻𝑻𝑫𝑫𝒑𝒑𝑫𝑫 𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫   
,where C is the free prednisolone concentration sampled after 1, 2 and 4 hours. For completeness in a secondary 
analysis, AUC from 0 to tmax (AUC0-tmax) and from 0 to infinity (AUC0-inf), the maximum measured concentration (Cmax) 
and the elimination rate constant (ke) of total and free prednisolone were also estimated based on non-compartmental 
analysis using the linear trapezoidal rule (with any extrapolation done assuming first-order pharmacokinetics). All 
exposure parameters were adjusted for prednisolone dose. All calculations were carried out using STATA 12.1 
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(StataCorp, College Station, Texas, USA).   
 
2.4 Statistical analysis 
 A pre-study power calculation determined that 53 subjects were sufficient to detect an 8 nmol·h/L/mg difference 
in free prednisolone dose-adjusted exposure, with a power of 80% and an alpha of 5%. Based on a previous study [16], 
the standard deviation (SD) was assumed to be 10 nmol·h/L/mg. Descriptive statistics used were median with 10th and 
90th percentile for continuous variables and percentages for categorical variables. Equality tests of patient characteristics 
were done using Wilcoxon rank-sum test. Parameter distribution plots and a Shapiro-Wilk test were used to check the 
pharmacokinetic parameters for departure from approximate normal distribution (results not shown). A students T-test 
or Wilcoxon rank-sum test was then used as appropriate, depending on the P-value of the Shapiro-Wilk test with a cut-
off value of 0.05. Regression analysis was performed to identify significant explanatory covariates on prednisolone 
pharmacokinetics. All analyses were carried out using STATA 12.1 (StataCorp, College Station, Texas, USA). 
 
3 RESULTS 
3.1 Participants 
Fifty-nine patients were enrolled in the study. Two patients did not attend for blood sampling and one patient 
inadvertently took his morning medication prior to blood sampling. One patient was treated with azathioprine, and 
neither tacrolimus nor cyclosporine. Thus, data from 55 patients were eligible for analysis. Table 1 provides the 
baseline demographic and clinical characteristics of this cohort. Twenty-one (38%) of the patients were treated with 
cyclosporine and 34 (62%) were treated with tacrolimus. The groups were comparable with regard to age, body weight, 
glomerular filtration rate (GFR), haematocrit and albumin. Time post-transplantation trended towards being greater in 
the cyclosporine group explaining the slightly lower prednisolone dose in this group (a result of the common practice to 
slowly taper prednisolone dose over time). Total bilirubin was normal in both groups but slightly, and statistically 
significantly, greater in the cyclosporine group (Table 1). Use of known CYP3A4 and/or p-gp inhibitors diltiazem 
and/or lercanidipine was more frequent in the cyclosporine compared with the tacrolimus cohort (76% versus 44%) 
(Table 1).   
 
3.2 Dose adjusted prednisolone exposure 
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 Figure 1 shows total and free prednisolone concentration-time profiles obtained in the 55 patients 
included in the final analysis. Prednisolone pharmacokinetic parameters in patients receiving cyclosporine versus 
tacrolimus are compared in Table 2. Primary analysis: Based on LSS estimation, no significant difference in mean (SD) 
dose adjusted total prednisolone AUC from 0 to 6 hours post-dose (dAUC0-6) or mean (SD) dose adjusted free 
prednisolone AUC from 0 to 12 hours (dAUC0-12) was observed between the cyclosporine and tacrolimus groups [449 
(86) versus 428 (103) nmol·h/L/mg, p=0.43 and 32 (11.0) versus 30 (9.5) nmol·h/L/mg, p= 0.51, respectively]. 
Secondary analysis: The elimination constant of free prednisolone ke was significantly lower in the cyclosporine group 
[0.164 h-1 (0.023) versus 0.175 h-1 (0.028), p=0.04]. All other pharmacokinetic parameters were similar between the 
groups. Regression analysis indicated that body weight was an important covariate for prednisolone dAUC. However, 
even after adjusting for this, no significant difference in pharmacokinetic parameters was detected between the groups 
(data not shown). There was no significant effect of use of diltiazem and/or lercanidipine on prednisolone 
pharmacokinetic parameters (data not shown). A single patient reported use of carbamazepine.    
 
4 DISCUSSION 
This study is the first to compare the pharmacokinetics of prednisolone in adult male kidney transplant 
recipients on long term cyclosporine versus tacrolimus therapy. No detectable impact of cyclosporine on total and free 
prednisolone exposure was observed, with the implication being that no adjustment in prednisolone dose is necessary 
when switching a transplant patient between calcineurin inhibitors. 
Five studies, with from 16 to 64 subjects, published between 1984 and 2004 compared prednisolone 
pharmacokinetics in patients treated with azathioprine or cyclosporine [8-10, 12, 14]. All studies found lower 
prednisolone clearance and/or increased prednisolone AUCs in the cyclosporine group. If it weren’t for two 
contradicting studies published in 1987 and 1988 the interaction would have been firmly established. The study 
published in 1987 compared 25 kidney transplant recipients treated with cyclosporine with 25 patients on 
azathioprine[11]. No significant difference between the groups was detected for free (unbound) and total prednisolone 
metabolic clearance, renal clearance, volume of distribution and systemic availability. The authors questioned the 
validity of the previous studies, highlighting multiple methodological issues including unequal age and sex distribution, 
lack of information on the use of other potentially interacting medications, failure to account for prednisolone dose and 
insufficient duration of pharmacokinetic sampling and not measuring free prednisolone exposure. In 1988 one more 
study compared clearance of free prednisolone before and after kidney transplantation and also found no difference, 
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albeit in a small population of 6 patients[13]. 
  These methodological issues have all been addressed by our study. For the first time, we chose to study 
exclusively male patients.  
There is evidence to support an impact of sex, and even hormonal cycle variation, on prednisolone exposure in 
fertile women [17, 18]. The most recent of the previously published cyclosporine-prednisolone interaction studies 
reported higher dose adjusted prednisolone exposure (348 nmol·h/L/mg prednisolone) for 28 patients on cyclosporine 
compared to 15 patients on azathioprine (285 nmol·h/L/mg prednisolone). However, prednisolone AUC was also found 
to be higher in females compared to males (415 versus 297 nmol·h/L/mg  prednisolone) [14], with the highest AUCs 
seen in cyclosporine treated women on estrogen supplements (median 595 nmol·h/L/mg prednisolone). This suggests 
that the unbalanced distribution of sex in this study (i.e. 15 women in the cyclosporine group (54%) versus 5 (33%) in 
the azathioprine group) might at least partially explain the observed difference in prednisolone exposure. 
Antihypertensive therapy with lercanidipine or diltiazem was more common in the cyclosporine group (76%) 
than in the tacrolimus group (44%). This is because diltiazem is a popular cyclosporine adjuvant because of its dose 
(cost) saving effect, owing to its inhibition of CYP3A4, in addition to controlling the blood pressure (hypertension is a 
common adverse effect of cyclosporine). In the analysis it is important to control for use of diltiazem and lercanidipine 
because the exerted inhibition of CYP3A4 and p-gp might affect the pharmacokinetics of prednisolone, which in this 
case might introduce bias in favour of rejecting the null hypothesis of cyclosporine not interacting with prednisolone 
pharmacokinetics. However, no effect of lercanidipine and/or diltiazem use on prednisolone pharmacokinetics was 
detected. 
It is well established that it is the free fraction of drugs that are biologically active. Previous studies have 
therefore also been criticized for only measuring total prednisolone. Moreover, the choice of assay might be of 
importance. Specifically the use of immunoassays has been criticized for introducing a risk of misinterpretation caused 
by cross reactivity of prednisolone and cortisol [11, 19]. In the present study we estimated the pharmacokinetic 
parameters based on both free and total prednisolone concentrations determined exclusively using state of the art ultra-
high performance liquid chromatography (UHPLC) with tandem mass spectrometric detection. 
The previous studies discussed above all used azathioprine as comparator for cyclosporine. Our study is the 
first to investigate the cyclosporine prednisolone interaction by using tacrolimus as comparator. Despite tacrolimus 
being a CYP3A4 substrate, there is no indication in the literature suggesting significant p-gp/CYP3A4 inhibiting or 
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inductive properties [20, 21]. Theoretically, a study with a control group not using a calcineurin inhibitor would be 
ideal, but is not a protocol practiced by the Princess Alexandra Hospital transplant unit. 
In a secondary analysis ke of free prednisolone was significantly lower in patients on cyclosporine compared to 
the tacrolimus. While this did not translate into a significant increase in free prednisolone exposure the finding is 
interesting because it suggests that cyclosporine may in fact influence elimination of prednisolone, albeit in a subtle and 
non-clinically relevant way. P-gp plays an excretory role for prednisolone not only in the liver, but also in the kidney 
(up to 25% of prednisolone is excreted unchanged in the urine [22, 23]), and cyclosporine is extensively bound to liver 
and kidney tissue [24-26]. One possible explanation for the observed results is that the concentration of cyclosporine in 
the intestinal mucosa is too low and/or too transient to inhibit the absorption of prednisolone to a degree that impacts on 
exposure, but high and consistent enough in the liver and/or kidney to reduce the intrinsic free prednisolone clearance in 
these organs and thereby affecting the slope of the terminal part of the elimination curve. However, it must be borne in 
mind that this study was not designed to specifically demonstrate a difference in elimination constants and that the ke 
estimates are based on limited data only. 
 
5 CONCLUSION 
This study did not detect a difference in total and free prednisolone exposure in adult male patients on 
cyclosporine or tacrolimus therapy. Hence, there is no need for prednisolone dose adjustment when substituting 
cyclosporine for tacrolimus (or vice versa) in adult male transplantation recipients.  
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Figure 1. Total (a) and free (b) prednisolone concentrations from 0 to 6 hours post-dose in 55 adult kidney 
transplant recipients on either tacrolimus (triangles) or cyclosporine (circles). 
a) 
   
b) 
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Tabel 1. Demographic characteristics of the 55 patients studied 
Characteristic Cyclosporine cohorta Tacrolimus cohorta P-value 
Number of patients (n) (all male) 21 (20 Caucasians) 34 (32 Caucasians) - 
Age (years) 61 [45-64] 55 [36-64] 0.17 
Body weight (kg) 82 [70-119] 85 [66-112] 0.87 
Serum creatinine (µmol/L) 132 [104-191] 137 [101-205] 0.48 
Glomerular filtration rateb (mL/min) 68 [39 - 97] 67 [35-92] 0.63 
Haematocrit (fraction) 0.41 [0.37-0.44] 0.41 [0.34-0.46] 0.94 
Albumin (g/L) 40 [36-43] 39 [36-43] 0.52 
Total bilirubin (µmol/L)  17 [14-24] 14 [8-17] <0.01 
Time post-transplantation (months) 109 [30-189] 43 [16-217] 0.07 
Prednisolone dose (mg) 5 [5-6] 5 [5-8] 0.02 
Cyclosporine/tacrolimus total daily dose (mg)  175 [100-225] 3 [1.5-8] - 
Concomitant diltiazem and/or lercanidipine (n (%)) 16 (76%) 15 (44%) - 
Concomitant mycophenolate mofetil (n(%)) 17 (81%) 28 (82%) - 
Concomitant trimethoprim-sulfamethoxazole (n(%)) 2 (10%) 6 (18%) - 
a- Results presented as median [10th-90th percentile], unless specified otherwise  
b- Calculated using the Cockcroft-Gault equation 
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 Table 2. Comparison of prednisolone pharmacokinetic parameters adjusted for dose in patients receiving 
cyclosporine versus tacrolimus 
Parameter Cyclosporine cohorta Tacrolimus cohorta P-value 
Primary analysis (limited sampling strategy) 
Total prednisolone dAUC0-6 h (nmol·h/L/mg) 449 [86] 428 [103] 0.43c 
Free prednisolone dAUC0-12 h (nmol·h/L/mg) 32 [11.0] 30 [9.5] 0.51c 
Secondary analysis (trapezoidal methodb) 
Total prednisolone dCmax (nmol/L/mg) 105 [18] 105 [23] 1.00c 
Free prednisolone dCmax (nmol/L/mg) 7.4 [2.8] 6.7 [2.5] 0.43d 
Total prednisolone dAUC0-inf (nmol·h/L/mg) 976 [211] 949 [219] 0.65d 
Free prednisolone dAUC0-inf (nmol·h/L/mg) 44.4 [14.9] 41.7 [10.9] 0.45c 
Total prednisolone ke (h-1) 0.186 [0.040] 0.181 [0.036] 0.50d 
Free prednisolone ke (h-1) 0.164 [0.023] 0.175 [0.028] 0.04d 
a – Results presented as mean [SD] 
b –Sum of trapezes and extrapolating from 24 hours to infinity using linear extension of last 3 observations and 
assuming C0 = C24 
c – Student’s T-test 
d – Wilcoxon rank-sum test 
dAUC – dose adjusted area under the plasma concentration time curve, dCmax – dose adjusted maximal observed plasma 
concentration, ke - elimination constant derived using C4, C6 and C24 (=C0)  
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